CreativeOne Wealth LLC Grows Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

CreativeOne Wealth LLC lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,167 shares of the medical equipment provider’s stock after buying an additional 499 shares during the quarter. CreativeOne Wealth LLC’s holdings in Lantheus were worth $567,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Signaturefd LLC grew its position in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares in the last quarter. GAMMA Investing LLC increased its stake in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares during the period. UMB Bank n.a. lifted its holdings in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus in the third quarter worth $51,000. Finally, Nkcfo LLC purchased a new stake in shares of Lantheus during the second quarter worth $47,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $89.27 on Friday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The firm has a market capitalization of $6.21 billion, a P/E ratio of 14.85 and a beta of 0.51. The company’s fifty day moving average price is $101.34 and its 200 day moving average price is $97.12.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Truist Financial reissued a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities decreased their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Finally, Redburn Atlantic initiated coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target for the company. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $125.71.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.